NIH Grant Funds Study of Protein That May Drive Lupus

A new $1.7 million National Institutes of Health (NIH) grant will support research into a protein that may help explain why systemic lupus erythematosus (SLE) develops and how it might be treated more precisely.

The project, led by Carol Webb, Ph.D., at the University of Oklahoma College of Medicine, focuses on a protein called ARID3a, which appears in higher numbers in the B cells of people with lupus. B cells are immune cells that produce antibodies, including the harmful autoantibodies that attack the body’s own tissues in lupus.

Webb’s research suggests that ARID3a may disrupt an important “safety check” during early B cell development. Normally, immature B cells that recognize the body’s own tissues are removed before they can cause harm. In people with lupus, however, some of these cells appear to escape this process, potentially allowing autoantibodies to form.

The newly funded project will investigate the genes controlled by ARID3a, examine how it alters B-cell development, and test whether blocking the protein can reduce lupus symptoms in animal models.

Understanding how these harmful antibodies arise is a major focus of lupus research. For example, research supported by GAI has explored how antibodies triggered by Epstein–Barr virus (EBV) may cross-react with human DNA through a process called molecular mimicry, potentially contributing to lupus development. Together, studies like these aim to uncover both the triggers and the immune system changes that allow autoimmune responses to take hold.

By identifying specific pathways involved in lupus, researchers hope to move toward more targeted therapies that address the root causes of the disease rather than broadly suppressing the immune system.